Editor's Choice
Access IntelliDoctor for Free: Answers to all medical questions with our AI-based platform
4 Mar, 2024 | 10:44h | UTCWatch a video with a demonstration of IntelliDoctor answering a series of medical questions in real-time (video lasts around 6 minutes).
See IntelliDoctor answer a complex diagnostic challenge in real-time (video lasts around 2 minutes).
We are excited to introduce IntelliDoctor (https://www.intellidoctor.ai/en), a groundbreaking AI platform free for medical professionals, redefining the resolution of medical queries. Utilizing sophisticated AI technology, including advanced prompt engineering and Retrieval Augmented Generation (RAG), IntelliDoctor provides evidence-based answers to complex clinical questions.
Our AI system rapidly analyzes open academic sources, delivering reliable responses typically within 10-15 seconds. We are dedicated to offering real-time academic insights, providing healthcare professionals with accurate, data-driven support.
Signing up is straightforward—no personal information is required, just a Gmail account. Step into the future of medical inquiry with IntelliDoctor. Experience our innovative AI solutions now, available at no cost for a limited time. Visit IntelliDoctor and enhance your medical practice with the power of AI.
Introducing IntelliDoctor: The Future of Medical Inquiry for Medical Professionals
26 Feb, 2024 | 11:21h | UTCWe are thrilled to introduce IntelliDoctor, an innovative platform designed specifically for medical professionals, aiming to revolutionize the way medical inquiries are addressed. At IntelliDoctor, we understand the critical need for accurate, timely, and evidence-based information in the medical field. Our platform leverages advanced AI technology, including sophisticated prompt engineering and Retrieval Augmented Generation (RAG), to provide precise answers to clinical questions.
IntelliDoctor’s core mission is to support healthcare professionals by delivering real-time academic insights. Our AI system meticulously searches open academic sources to offer reliable responses based on verifiable research. This process ensures that every answer we provide is not only immediate but also grounded in credible data, with a typical response time of 10-15 seconds.
Our platform is user-friendly and designed to be accessible to medical professionals worldwide. Currently available in English (https://www.intellidoctor.ai/en) and Portuguese (https://www.intellidoctor.ai/pt), IntelliDoctor welcomes users to experience its capabilities in any language, adapting to the global nature of the medical community. For a limited time, we are offering free access to our platform, allowing medical professionals to explore and benefit from our advanced AI-driven solutions.
Getting started with IntelliDoctor is straightforward: no personal information is required, just a Gmail account. We invite you to join us in this medical revolution, where AI technology meets clinical expertise to enhance patient care and support medical professionals. Experience the future of medical inquiry with IntelliDoctor and be part of the transformation in healthcare innovation.
AI-Powered GPTs for Doctors: Evidence-Based Medicine & Clinical Decision Support Prompts
17 Dec, 2023 | 18:39h | UTCWelcome to IntelliDoctor’s innovative collection of AI-Powered GPT Prompts, specifically designed for doctors seeking to enhance their clinical practice with evidence-based information. Utilizing the latest Natural Language Processing (NLP) technology, our prompts provide decisive support in various aspects of medicine, from identifying drug interactions to differential diagnoses, treatments, and more. Each prompt has been meticulously developed to provide accurate and up-to-date information, assisting healthcare professionals in quickly accessing crucial data for patient care decision-making. Important: access to these specialized prompts requires a GPT-4 subscription. With our tool, doctors can easily obtain relevant clinical insights, optimizing time and improving the quality of medical care. Explore our 6 specialized prompts and discover how artificial intelligence can transform your medical practice.
Disclaimer: These tools are intended for use by doctors and healthcare professionals only, and are not recommended for use by other individuals. GPT models can make errors, so please use them with extreme caution and always verify the information before applying it to patient care.
- All Purpose: Comprehensive solutions for general medical inquiries.
- Medications: Detailed information on various medications.
- Interactions: Analysis of potential drug interactions.
- Diseases: Information on a wide range of diseases.
- Signs and Symptoms: Assistance in interpreting clinical signs and symptoms.
- Differential Diagnosis: A tool to aid in differential diagnosis.
RCT: No difference in ICU length of stay or 90-day mortality between tight and liberal glucose control
2 Oct, 2023 | 11:25h | UTCStudy Design and Population: This randomized controlled trial assessed the effects of tight versus liberal glucose control on the length of ICU stay in critically ill patients. A total of 9,230 patients were included, with 4,622 in the liberal-control group (insulin initiation when blood glucose levels exceeded 215 mg/dL) and 4,608 in the tight-control group (blood glucose targeted between 80 and 110 mg/dL). In both groups, parenteral nutrition was withheld during the first week of ICU admission. The primary endpoint was the duration of ICU stay, and 90-day mortality served as a key safety outcome.
Main Findings: No significant differences were observed in the primary endpoint, the length of ICU stay, between the two groups (hazard ratio 1.00; 95% CI, 0.96 to 1.04; P=0.94). The 90-day mortality rates were also similar (10.1% in the liberal-control group vs. 10.5% in the tight-control group, P=0.51). Incidences of severe hypoglycemia were low and statistically similar in both groups (1.0% in the tight-control group vs. 0.7% in the liberal-control group). Secondary outcomes, including new infections and the duration of respiratory and hemodynamic support, showed no significant differences. However, lower incidences of severe acute kidney injury and cholestatic liver dysfunction were observed in the tight-control group.
Implications & Limitations: The study supports existing evidence that tight glucose control doesn’t provide substantial benefits in reducing ICU stay duration or mortality. This suggests that a more liberal approach to glucose control may be preferable in most ICU settings, especially to minimize hypoglycemia risk. Key limitations of the study include its narrow focus on the absence of early parenteral nutrition, which could limit generalizability, and the inability to blind caregivers to treatment assignments. Future research should investigate the impact of tight glucose control in various patient subgroups and under different nutritional conditions.
RCT: Propafenone leads to quicker sinus rhythm restoration than amiodarone in supraventricular arrhythmias related to septic shock
1 Oct, 2023 | 15:19h | UTCStudy Design & Population: The research was a two-center, prospective, controlled parallel-group, double-blind trial involving 209 septic shock patients who had new-onset supraventricular arrhythmia and a left ventricular ejection fraction above 35%. Patients were randomized to receive either intravenous propafenone (70 mg bolus followed by 400–840 mg/24 h) or amiodarone (300 mg bolus followed by 600–1800 mg/24 h).
Main Findings: The primary outcomes focused on the proportion of patients in sinus rhythm 24 hours post-infusion, time to the first sinus rhythm restoration, and arrhythmia recurrence rates. No significant difference was observed in 24-hour sinus rhythm rates between the propafenone (72.8%) and amiodarone (67.3%) groups (p=0.4). Time to the first rhythm restoration was significantly shorter for the propafenone group (median 3.7 hours) compared to the amiodarone group (median 7.3 hours, p=0.02). Recurrence of arrhythmia was notably lower in the propafenone group (52%) than in the amiodarone group (76%, p<0.001). In the subgroup of patients with a dilated left atrium, amiodarone appeared to be more effective.
Implications & Limitations: The study suggests that while propafenone doesn’t offer better rhythm control at 24 hours compared to amiodarone, it does provide faster cardioversion and fewer arrhythmia recurrences, especially in patients with a non-dilated left atrium. No significant differences were observed in clinical outcomes, such as ICU or long-term mortality, between propafenone and amiodarone in the trial. Limitations include potential underpowering of the study and the inability to fully account for the impact of multiple covariates involved in the complex therapy of septic shock.
Commentary on Twitter:
Propafenone?70 mg bolus+ 400-840 mg/24h vs amiodarone?300 mg + by 600-1800 mg/24h for SVA in septic shock, RCT
?propafenone not better for rhythm control at 24h but excellent hemodynamic safety profile, cardioverting faster & fewer recurrences#FOAMCc
?https://t.co/GVuoxPD7Hy pic.twitter.com/rRlj00x71p— Intensive Care Medicine (@yourICM) September 13, 2023
LinksMedicus.com: operations paused for the foreseeable future.
23 Aug, 2023 | 12:44h | UTCDear LinksMedicus Subscribers,
I regret to inform you that LinksMedicus.com will be pausing operations for the foreseeable future. After 12 years and over 30.000 curated articles in all specialties, I will now focus on my clinical practice.
Best regards to all.
Euclides Cavalcanti
São Paulo, Brazil
Crossover RCT | Using one-size cuff results in major inaccuracy in BP readings across varying arm sizes
11 Aug, 2023 | 15:41h | UTCEffects of Cuff Size on the Accuracy of Blood Pressure Readings: The Cuff(SZ) Randomized Crossover Trial – JAMA Internal Medicine (free for a limited period)
Commentaries:
When it comes to blood pressure cuffs, size matters – MedicalResearch.com
One-size-fits-all blood pressure cuffs ‘strikingly inaccurate,’ study says – CNN
Related:
Commentary on Twitter
Using a regular blood pressure (BP) cuff regardless of individual’s arm size resulted in 3.6 mmHg lower systolic BP when a regular cuff was one size too-large, and 4.8 and 19.5 mmHg higher when a regular cuff was one and two sizes too small. https://t.co/ZKnGfWc9fy
— JAMA Internal Medicine (@JAMAInternalMed) August 7, 2023
Perspective | Clinicians debate the usefulness of NAFLD name change
11 Aug, 2023 | 15:39h | UTCClinicians debate the usefulness of NAFLD name change – MDedge
Original article: From NAFLD to MASLD | New consensus changes fatty liver disease terminology to avoid stigmatization
Presented at ASRS Meeting | Studies link GLP-1 agonists to progression of diabetic retinopathy
11 Aug, 2023 | 15:38h | UTCStudies link GLP-1 agonists to progression of diabetic retinopathy – MDedge
Study | The high financial and human cost of quality metric reporting in hospitals
11 Aug, 2023 | 15:36h | UTCThe Volume and Cost of Quality Metric Reporting – JAMA (link to abstract – $ for full-text)
Author Interview: The Costs of Quality Reporting – JAMA
Commentaries:
The Cost of “Quality” – Emergency Medicine Literature of Note
How John Hopkins spent $5m and 108,478 hours on quality reporting in one year – HealthLeaders
The cost of quality metric reporting – Becker’s Hospital Review
Study | Uncovering the potential overuse of laboratory tests by combining cost, abnormal result proportion, and physician variation
11 Aug, 2023 | 15:34h | UTC
[News Release] RCT | Semaglutide 2.4 mg reduces cardiovascular risk by 20% in adults with CVD & obesity
9 Aug, 2023 | 15:40h | UTCCommentaries:
SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity – TCTMD
Perspective | Creation and adoption of large language models in medicine
9 Aug, 2023 | 15:38h | UTCCreation and Adoption of Large Language Models in Medicine – JAMA (free for a limited period)
Commentary: Rethinking large language models in medicine – Stanford Medicine
Perspective | An AI-enhanced electronic health record could boost primary care productivity
9 Aug, 2023 | 15:36h | UTCAn AI-Enhanced Electronic Health Record Could Boost Primary Care Productivity – JAMA (free for a limited period)
Perspective | Large language models answer medical questions accurately, but can’t match clinicians’ knowledge
9 Aug, 2023 | 15:35h | UTCLarge Language Models Answer Medical Questions Accurately, but Can’t Match Clinicians’ Knowledge – JAMA (free for a limited period)
Perspective | Artificial-intelligence search engines wrangle academic literature
9 Aug, 2023 | 15:33h | UTCArtificial-intelligence search engines wrangle academic literature – Nature
Research Letter | GPT-3.5 and GPT-4 show low accuracy in citing journal articles
9 Aug, 2023 | 15:31h | UTCAccuracy of Chatbots in Citing Journal Articles – JAMA Network Open
Commentary on Twitter
21% of medical journal articles cited by GPT-4 were found to be fake; GPT-3.5 cited an estimated 98% fake articles. Narrower topics had more fake articles than broader topics. Despite its promise, ChatGPT is currently not a reliable source of medical data. https://t.co/DCTIkT1OkZ
— JAMA Network Open (@JAMANetworkOpen) August 9, 2023
M-A | Nearly 37% of elderly outpatients are at risk due to potentially inappropriate medication use
8 Aug, 2023 | 13:37h | UTC
M-A | Approximately 25 min/day of walking can boost function and cut adverse events in acutely hospitalized elders
8 Aug, 2023 | 13:35h | UTC
Proposed algorithm for appropriate fluid management in acute pancreatitis
8 Aug, 2023 | 13:33h | UTCFluid treatment in acute pancreatitis: a careful balancing act – British Journal of Surgery
Related:
Update on the management of acute pancreatitis – Current Opinion in Critical Care
Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis – New England Journal of Medicine
Acute Pancreatitis: Diagnosis and Treatment – Drugs
Evidence-Based Disposition of Acute Pancreatitis – emDocs
Pancreatitis – National Institute for Health and Care Excellence
Research: Endoscopic or Surgical Step-up Approach for Infected Necrotising Pancreatitis
Evidence-Based Approach to the Surgical Management of Acute Pancreatitis – The Surgery Journal
Multinational Study | No correlation between Covid-19 and onset of type 1 diabetes in children
8 Aug, 2023 | 13:32h | UTC
Perspective | Will unpredictable side effects dim the promise of new Alzheimer’s drugs?
8 Aug, 2023 | 13:30h | UTCWill unpredictable side effects dim the promise of new Alzheimer’s drugs? – Science (a few articles per month are free)
Related:
RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns
RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns
NICE Updated Guideline | Venous thromboembolic diseases
7 Aug, 2023 | 15:05h | UTC
Review | Management of worsening heart failure with reduced ejection fraction
7 Aug, 2023 | 15:03h | UTC
Commentary on Twitter
How do you manage patients with worsening #HFrEF? This review by @SJGreene_md, @JavedButler1 and team provides the latest evidence-based guidance for the medical management of this high-risk population. https://t.co/REAqsrHDjI#JACC #CardioTwitter @ShelleyZieroth @DCRINews pic.twitter.com/rZYD25vCoG
— JACC Journals (@JACCJournals) August 5, 2023
Cohort Study | High-sensitivity troponin’s role in assessing MI and CV death risk in stable CAD patients
7 Aug, 2023 | 15:01h | UTCHigh-Sensitivity Cardiac Troponin for Risk Assessment in Patients With Chronic Coronary Artery Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentaries:
High-Sensitivity Troponin Assays May Stratify Risk in Chronic CAD – TCTMD
Commentary on Twitter
In patients with chronic CAD, an elevated #troponin identifies those more likely to have MI or CV death. Routine troponin testing in this setting could inform patient selection for additional treatment. https://t.co/T4HfidPwOA#JACC #cvCAD #CardioTwitter #cvPrev #cvMI pic.twitter.com/2IOU8jsFPj
— JACC Journals (@JACCJournals) August 1, 2023